Sugi Predict

Sugi Predict / Targets / TLR3

TLR3

Toll-like receptor 3 · O15455 · TLR3 on Sugi Atlas →

2,018 patent compounds predicted against TLR3, 1,592 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13619867 SCHEMBL13619867 0.42 3/20
SCHEMBL14440467 SCHEMBL14440467 0.42 3/20
SCHEMBL19030616 SCHEMBL19030616 0.40 3/20
SCHEMBL19838486 SCHEMBL19838486 1.00 2/20
SCHEMBL19838431 SCHEMBL19838431 0.90 2/20
SCHEMBL19838366 SCHEMBL19838366 0.81 2/20
SCHEMBL19838376 SCHEMBL19838376 0.78 2/20
SCHEMBL19838367 SCHEMBL19838367 0.77 2/20
SCHEMBL19838663 SCHEMBL19838663 0.77 2/20
SCHEMBL19838440 SCHEMBL19838440 0.76 2/20
SCHEMBL19838343 SCHEMBL19838343 0.73 2/20
SCHEMBL19838469 SCHEMBL19838469 0.72 2/20
SCHEMBL19838336 SCHEMBL19838336 0.72 2/20
SCHEMBL19838361 SCHEMBL19838361 0.71 2/20
SCHEMBL19838445 SCHEMBL19838445 0.71 2/20
SCHEMBL19838399 SCHEMBL19838399 0.71 2/20
SCHEMBL19838348 SCHEMBL19838348 0.70 2/20
SCHEMBL19838365 SCHEMBL19838365 0.70 2/20
SCHEMBL10752810 SCHEMBL10752810 0.70 2/20
SCHEMBL19838425 SCHEMBL19838425 0.69 2/20

Clinical trials — most relevant to TLR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic PHASE2/PHASE3WITHDRAWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients PHASE1/PHASE2COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients PHASE1/PHASE2COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers PHASE1COMPLETED
The Effects of GLA on Human Volunteers PHASE1COMPLETED
Role of TLR4 in Environmental Asthma PHASE1COMPLETED
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 EARLY_PHASE1UNKNOWN
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer EARLY_PHASE1COMPLETED
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
TLR4 Polymorphisms and Risk of Skin Cancer nanCOMPLETED
Expression of Toll-like Receptors 3 , 7 and 9 in Peripheral Blood Mononuclear Cells of COVID-19 Patients nanUNKNOWN
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches nanUNKNOWN
Neuro-Immune Interactions in the Gut nanCOMPLETED
Biomarkers of Trained Immunity Following MMR Vaccination nanCOMPLETED
Deep Phenotyping of Cutaneous Lupus Erythematosus nanUNKNOWN
X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study nanCOMPLETED
The Suppression of Toll Like Receptors by Insulin nanCOMPLETED
Mucins and Toll-like Receptors in Asthma nanCOMPLETED
Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis nanCOMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis nanUNKNOWN
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients nanCOMPLETED
Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection nanCOMPLETED
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis). nanUNKNOWN
The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Population nanRECRUITING
Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) nanUNKNOWN
Bacteremia in Intensive Care Unit (ICU) nanUNKNOWN
Inflammation Regulation in Obese Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TLR3 binder may also engage these)

ProteinNameSimilarity
Q99MB1 — 1.000 Q99MB1 →
Q5TJ59 — 1.000 Q5TJ59 →
Q0PV50 — 0.999 Q0PV50 →
Q9QX05 — 0.997 Q9QX05 →
Q2V898 — 0.996 Q2V898 →
Q9TSP2 — 0.996 Q9TSP2 →
Q9TTN0 — 0.995 Q9TTN0 →
Q9GL65 — 0.995 Q9GL65 →
TLR4 Toll-like receptor 4 0.995 landscape →
Q6R5N8 — 0.994 Q6R5N8 →
Q8SPE8 — 0.994 Q8SPE8 →
Q62192 — 0.993 Q62192 →
Q68Y56 — 0.993 Q68Y56 →
Q9MYW3 — 0.992 Q9MYW3 →
Q9QUK6 — 0.991 Q9QUK6 →
Q8SPE9 — 0.990 Q8SPE9 →
P58727 — 0.990 P58727 →
Q9WV82 — 0.990 Q9WV82 →
Q9JLF7 — 0.989 Q9JLF7 →
Q99467 — 0.989 Q99467 →
TLR5 Toll-like receptor 5 0.989 landscape →
Q58A48 — 0.988 Q58A48 →
TLR8 Toll-like receptor 8 0.988 landscape →
Q6AXL3 — 0.986 Q6AXL3 →
P58682 — 0.986 P58682 →
V5NAL9 — 0.985 V5NAL9 →
Q65Z91 — 0.985 Q65Z91 →
Q9DE66 — 0.984 Q9DE66 →
O62702 — 0.984 O62702 →
P08953 — 0.983 P08953 →